Market Overview

Tricida Announces Pricing of Initial Public Offering

Share:

Tricida, Inc., a pharmaceutical company focused on the development and
commercialization of TRC101, a non-absorbed, orally-dosed polymer drug
designed to treat metabolic acidosis in patients with chronic kidney
disease, today announced the pricing of its initial public offering of
11,700,000 shares of its common stock at a public offering price of
$19.00 per share for total gross proceeds of approximately $222.3
million, before deducting underwriting discounts and commissions and
other offering expenses payable by Tricida. Tricida has granted to the
underwriters a 30-day option to purchase up to 1,755,000 additional
shares of common stock at the initial public offering price, less
underwriting discounts and commissions. The shares are expected to begin
trading on The Nasdaq Global Select Market on June 28, 2018 under the
symbol "TCDA." The offering is expected to close on July 2, 2018,
subject to customary closing conditions.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and
Company, LLC are acting as joint book-running managers for the offering.
The offering is being made only by means of a prospectus, copies of
which may be obtained, when available, from: Goldman Sachs & Co. LLC,
Prospectus Department, 200 West Street, New York, NY 10282, telephone:
1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com;
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204, or by
emailing prospectus-eq_fi@jpmchase.com;
or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, or
facsimile: 631-254-7140.

A registration statement relating to these securities has been filed
with the U.S. Securities and Exchange Commission and has been declared
effective under the Securities Act of 1933, as amended. This press
release does not constitute an offer to sell or a solicitation of an
offer to buy the securities described above, nor shall there be any sale
of such securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or jurisdiction.

About Tricida

Tricida, Inc., is a pharmaceutical company focused on the development
and commercialization of TRC101, a non-absorbed, orally-dosed polymer
drug designed to treat metabolic acidosis in patients with chronic
kidney disease.

Forward-Looking Statement

This press release contains forward-looking statements within the
meaning of the U.S. federal securities laws. When used in this press
release, the words "expect," "approximately" or the negative of these
words and phrases or similar words or phrases that are predictions of or
indicate future events and that do not relate solely to historical
matters are intended to identify forward-looking statements. The
forward-looking statements contained in this press release reflect
Tricida's current views with respect to future events, and Tricida does
not undertake and specifically disclaims any obligation to update any
forward-looking statements.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com